| Theme |
The New Guideline for Liver Cancer Treatment |
| Title |
Treatment Algorithm for Hepatocellular Carcin om a According to the Official Japanese Guideline |
| Author |
Junichi Arita |
Hepato-Biliary and Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo |
| Author |
Nobuhisa Akamatsu |
Hepato-Biliary and Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo |
| Author |
Junichi Kaneko |
Hepato-Biliary and Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo |
| Author |
Yoshihiro Sakamoto |
Hepato-Biliary and Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo |
| Author |
Kiyoshi Hasegawa |
Hepato-Biliary and Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo |
| [ Summary ] |
The 4th edition of Japanese Society of Hepatology (JSH) HCC Guidelines was published in 2017. The treatment algorithm was modified to be integrated with the consensus guideline of JSH. Despite that, the total balance of treatment strategy has not been altered and the following points of change are noticed: (1) The first line of the flowchart was altered from degree of liver damage to Child-Pugh classification; (2) "Extrahepatic metastasis" and "vascular invasion" are included in the flow-chart body; (3) The term "chemotherapy" has been modified to "molecular targeted drug", indicating the use of sorafenib, and newly developed regorafenib and lenvatinib. These modifications were made to enable the easy use of the algorithm by all clinicians engaged in the practice of treating hepatocellular carcinoma. |